South Africa’s Biovac Institute strikes deal with BioNTech and Pfizer to produce 100 million Covid vaccines a year
The Cape Town-based Biovac Institute, Pfizer and BioNTech announced their collaboration to produce Covid vaccines in South Africa on Wednesday. The installation of equipment, technical transfers and on-site development will begin immediately to prepare the institute for the manufacturing process.
Pfizer and BioNTech assume that the South African facility will be incorporated into the vaccine supply chain at the end of 2021. If all processes go to plan, South Africa will be able to manufacture Pfizer-BioNTech Covid vaccinations in 2022. According to the collaboration declaration, “annual production will exceed 100 million doses”, which will all be distributed amongst the 55 member states of the African Union.
Breaking: 🇿🇦South Africa's @biovac_inst tapped to produce 100M doses annually of Pfizer-BioNTech COVID-19 vaccine exclusively for African Union in 2022.Tech transfer + setup beginning at Biovac; Pfizer expects facility to be ready by end of 2021. $PFE$BNTXpic.twitter.com/GSSV3GDWj7— Anjalee Khemlani (@AnjKhem) July 21, 2021
The recent collaboration comes as welcome news, with the CEO of Biovac, Dr Morena Makhoana, saying: “We believe this collaboration will create opportunity to more broadly distribute vaccine doses to people in harder-to-reach communities, especially those on the African continent.”
A report published on July 15 by the World Health Organization’s (WHO) Africa branch revealed how dire Covid vaccine inequity is. According to the data, out of Africa’s 1.3 billion population, only 1.5% are fully inoculated. The WHO had also warned about the surging case and death rates. One million cases were reported across the African continent in one month alone, as well as a 43% increase in the death toll in just one week.Also on rt.com US to donate 25 million vaccine doses to African countries under COVAX as continent struggles to weather third wave
Pfizer and BioNTech claim that their ethos is to make their vaccine as accessible as possible worldwide. Ugur Sahin, the CEO and co-founder of BioNTech, shared that “we aim to enable people on all continents to manufacture and distribute our vaccine whole ensuring the quality of the manufacturing process and doses.”
Pfizer and BioNTech have shipped over one billion Covid-19 vaccines to over 100 countries globally. The companies pledged in May to provide two billion doses, across two years, to low- and middle-income countries in 2021 and 2022.
Like this story? Share it with a friend!